M
Marie Danjoux
Researcher at University of Toulouse
Publications - 29
Citations - 2078
Marie Danjoux is an academic researcher from University of Toulouse. The author has contributed to research in topics: Liver transplantation & Transplantation. The author has an hindex of 15, co-authored 28 publications receiving 1825 citations. Previous affiliations of Marie Danjoux include French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Hepatitis E virus and chronic hepatitis in organ-transplant recipients.
Nassim Kamar,Janick Selves,Jean-Michel Mansuy,Leila Ouezzani,Jean-Marie Péron,Joelle Guitard,Olivier Cointault,Laure Esposito,Florence Abravanel,Marie Danjoux,Dominique Durand,Jean-Pierre Vinel,Jacques Izopet,Lionel Rostaing +13 more
TL;DR: The time from transplantation to diagnosis was significantly shorter and the total counts of lymphocytes and of CD2, CD3, and CD4 T cells were significantly lower in patients in whom chronic disease developed.
Journal ArticleDOI
Hepatitis E virus-related cirrhosis in kidney- and kidney-pancreas-transplant recipients.
Nassim Kamar,Jean-Michel Mansuy,Olivier Cointault,J. Selves,Florence Abravanel,Marie Danjoux,Phillippe Otal,L. Esposito,Dominique Durand,Jacques Izopet,Lionel Rostaing +10 more
TL;DR: It is concluded that HEV infection cannot only evolve to chronic hepatitis, but can also be responsible for rapidly progressing cirrhosis in organ‐transplant patients.
Journal ArticleDOI
A ‘DNA replication’ signature of progression and negative outcome in colorectal cancer
M-J Pillaire,Janick Selves,Karine Gordien,P. Gouraud,C. Gentil,Marie Danjoux,C. Do,Vincent Nègre,A. Bieth,Rosine Guimbaud,Didier Trouche,Philippe Pasero,Marcel Méchali,J S Hoffmann,Christophe Cazaux +14 more
TL;DR: The data suggest the existence of a ‘DNA replication signature’ that might represent a source of new prognostic markers that could help in understanding the molecular mechanisms underlying tumor progression in colorectal cancer patients.
Journal ArticleDOI
Prevalence, Incidence and Risk Factors for Donor‐Specific Anti‐HLA Antibodies in Maintenance Liver Transplant Patients
A. Del Bello,Nicolas Congy-Jolivet,Nicolas Congy-Jolivet,Fabrice Muscari,Laurence Lavayssière,L. Esposito,Isabelle Cardeau-Desangles,Juliette Guitard,Gaëlle Dörr,Bertrand Suc,J.-P. Duffas,Laurent Alric,Christophe Bureau,Marie Danjoux,Céline Guilbeau-Frugier,Antoine Blancher,Antoine Blancher,Lionel Rostaing,Lionel Rostaing,Nassim Kamar,Nassim Kamar +20 more
TL;DR: Monitoring for the development of DSAs in maintenance LT patients is useful in case of graft dysfunction and to identify patients with a high risk of developing liver fibrosis.
Journal ArticleDOI
De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients.
Arnaud Del Bello,Nicolas Congy-Jolivet,Nicolas Congy-Jolivet,Marie Danjoux,Fabrice Muscari,Laurence Lavayssière,Laure Esposito,Isabelle Cardeau-Desangles,Joelle Guitard,Gaëlle Dörr,David Milongo,Bertrand Suc,Jean Pierre Duffas,Laurent Alric,Christophe Bureau,Céline Guilbeau-Frugier,Lionel Rostaing,Lionel Rostaing,Nassim Kamar,Nassim Kamar +19 more
TL;DR: In conclusion, liver‐transplant patients with liver abnormalities should be screened for DSAs and AMR, and younger age, low exposure to calcineurin inhibitors, and noncompliance were predictive factors for de novo DSA formation.